Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
NCT00286793
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
76
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
AT-101
Sponsor
Ascenta Therapeutics